TY - T1的血清水平的可溶性粘附分子在短期和长期保持稳定Interferon-beta-1b治疗(P02.144) JF -神经学乔-神经病学SP - P02.144 LP - P02.144六世- 78 - 1补充非盟- Jorg克劳斯盟为何Zaunrieth盟——给Obregon首页-Castrillo盟——凯特琳Oppermann AU - Georg Pilz AU -彼得Wipfler盟Shahrzad Afazel AU -伊丽莎白Haschke-Becher盟Stefan Golaszewski AU -沃尔夫冈Hitzl AU -尤金Trinka盟安德里亚勒Y1 - 2012/04/24 UR - //www.ez-admanager.com/content/78/1_Supplement/P02.144.abstract N2 -目的:探讨IFN-beta-1b治疗是否会影响血清浓度的一组重要的可溶性粘附分子参与免疫细胞贩运。背景Interferon-beta-1b (IFN-beta-1b;BetaferonTM)都是有效和安全的治疗多发性硬化症(MS)。描述了几个IFN-beta-1b治疗的免疫调节效应,但确切的机制是不确定的。细胞粘附分子被认为是至关重要的免疫细胞迁移进入中枢神经系统。可溶性形式脱落进入外周血可能参与白细胞/内皮互动的微调和反馈机制。设计/方法:血清浓度的细胞间粘附molecules-1和3 (sICAM-1, 3),血管粘连molecule-1 (sVCAM-1),血小板内皮细胞粘附molecule-1 (sPECAM-1)和可溶性P -形式E-selectins IFN-1b-treatment下26名RRMS患者和19个健康对照进行了荧光bead-based技术。患者分为短期(n = 10,治疗持续时间:1年)、中期(n = 8,治疗持续时间:2 - 7岁),和长期(n = 8,治疗时间超过7年)组。测量在基线和后3、6、9和12个月的IFN-β-1b治疗short-term-treated组,并两次在6个月的中期和长期治疗组和控制。结果:比较治疗名RRMS患者(基线值)的血清浓度和控制显示无显著差异,可溶性形式的细胞粘附分子。血清水平的六个研究参数保持一致和稳定在所有时间点独立的治疗在短期内持续时间,中期和长期IFN-β-1b-treated病人组。结论:我们表明,血清浓度的六大可溶性粘附分子IFN-beta-1b治疗期间保持稳定。IFN-beta-1b疗法包括免疫调节效应除了可溶性粘附分子之间的动态平衡的变化及其cell-bound配体。支持:拜耳先灵葆雅制药公司、奥地利。Disclosure: Dr. Kraus has received personal compensation for activities with Biogen Idec, Bayer Pharmaceuticals Corporation, Sanofi-Aventis Pharmaceuticals, Merck-Serono, Novartis, Genzyme Corporation as a consultant. Dr. Kraus has received research support from Biogen Idec, Bayer Pharmaceuticals Corporation, Sanofi-Aventis Pharmaceuticals, Merck Serono, Novartis, Genzyme Corporation. Dr. Zaunrieth has nothing to disclose. Dr. Obregon-Castrillo has nothing to disclose. Dr. Oppermann has nothing to disclose. Dr. Pilz has nothing to disclose. Dr. Wipfler has nothing to disclose. Dr. Afazel has nothing to disclose. Dr. Haschke-Becher has nothing to disclose. Dr. Golaszewski has nothing to disclose. Dr. Hitzl has nothing to disclose. Dr. Trinka has received personal compensation for activities with UCB Pharma, Eisai Inc., Sunovion, Medtronic, Pfizer Inc, Ever-Neuropharma and GlaxoSmithKline, Inc. as a consultant and/or speaker. Dr. Trinka has received research support from UCB Pharma, Ever-Neuropharma, Medtronic and GlaxoSmithKline, Inc. Dr. Harrer has nothing to disclose.Tuesday, April 24 2012, 07:30 am-12:00 pm ER -